statin prophylaxis and inflammatory mediators following cardiopulmonary bypass a systematic review他汀类药物预防和炎症介质后心肺旁路系统回顾.pdf

Available online /content/13/5/R165 Vol 13 No 5 Open Access Research Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review 1 2 3 Catherine Morgan , Michael Zappitelli and Peter Gill 1Division of Nephrology, Department of Pediatrics, University of Alberta, 2B2-42 WC Mackenzie Health Sciences Centre, Edmonton, Alberta, T6G 2R7, Canada 2Montreal Childrens Hospital, McGill University Health Centre, 2300 Tupper Street, Montreal, Quebec, H3H 1P3, Canada 3Faculty of Medicine and Dentistry, University of Alberta, 2J2.00 WC Mackenzie Health Sciences Centre Edmonton, Alberta, T6G 2R7, Canada Corresponding author: Catherine Morgan, cmorgan@ualberta.ca Received: 3 Jul 2009 Revisions requested: 13 Aug 2009 Revisions received: 10 Sep 2009 Accepted: 20 Oct 2009 Published: 20 Oct 2009 Critical Care 2009, 13:R165 (doi:10.1186/cc8135) This article is online at: /content/13/5/R165 © 2009 Morgan et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Introduction Induction of an inflammatory response is thought Results Eight RCTs were included in the review, with the to have a significant role in the complications that follow number of trials for each inflammatory outcome being even more cardiopulmonary bypass (CPB). The statin drugs are limited. Pooled data demonstrated benefit with the use